Navigation Links
Oncolytics Biotech(R) Inc. Announces Second Quarter 2010 Results
Date:7/29/2010

---- 25,662,961 34,701,071 ------------------------------------------------------------------------- Property and equipment 222,312 208,320 Long term investment 684,000 684,000 ------------------------------------------------------------------------- 26,569,273 35,593,391 ------------------------------------------------------------------------- ------------------------------------------------------------------------- LIABILITIES AND SHAREHOLDERS' EQUITY Current Accounts payable and accrued liabilities 3,639,572 4,226,933 ------------------------------------------------------------------------- Shareholders' equity Share capital Authorized: unlimited number of common shares Issued: 61,569,969 (December 31, 2009 - 61,549,969) 131,980,274 131,908,274 Warrants 2,073,441 4,511,441 Contributed surplus 16,157,171 13,734,743 Deficit (127,281,185) (118,788,000) ------------------------------------------------------------------------- 22,929,701 31,366,458 ------------------------------------------------------------------------- 26,569,273 35,593,391 ------------------------------------------------------------------------- ------------------------------------------------------------------------- Oncolytics Biotech Inc. CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS (unaudited) Three Month Three Month Six Month
'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Issuance of 35th U.S. Patent
2. Oncolytics Biotech(R) Inc. To Host Conference Call to Discuss Updated U.K. Phase I/II Trial Head and Neck Cancer Data Being Presented at the ASCO Annual Meeting
3. Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
4. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
5. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
6. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
7. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
8. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
9. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
10. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
11. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... ANDS ) announced today that it will present ... on Tuesday,March 4, 2008 at 4:30 p.m. EST (1:30 ... Hotel in New York., Steve Worland, Ph.D., President ... an overview of Anadys and its two,development-stage product candidates, ...
... Vermillion, Inc.,(Nasdaq: VRML ) announced that on February ... Market LLC that indicated the Company is not in,compliance ... (i),a minimum of $2,500,000 in stockholders, equity; (ii) $35,000,000 ... net income from continuing,operations for the most recently completed ...
... Ltd., a wholly owned subsidiary of Forest Laboratories, ... and Mylan Inc. (NYSE: MYL ) have,amended ... the novel beta blocker Bystolic(TM) (nebivolol), which is,currently ... of hypertension.,The companies have agreed that Forest will ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference 2Vermillion Receives NASDAQ Notice of Non-Compliance 2Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement 2Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement 3
(Date:4/17/2014)... State University engineer has developed a patented technique ... explosive devices. The same technique could help police ... M. and Kay L. Theede chair in engineering ... and his research team have created a template-based ... car trunks. The distance detection method called ...
(Date:4/17/2014)... release is available in German . ... pay the protection money demanded of him, he can expect ... required, however, as fear of the consequences is enough to ... in parasitic birds, which lay their eggs in other birds, ... the brood parasites take their revenge by destroying the entire ...
(Date:4/17/2014)... conditions such as heart disease, epilepsy and pain, making ... there is still much scientists do not know about ... insight into the structure of sodium channels and, specifically, ... are responsible for ,fine-tuning, the activity of the channel. ... of the Journal of Biological Chemistry . , ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Structure of sodium channels different than previously believed 2
... a devastating wheat fungus isn,t threatening the state,s crops yet. ... the U.S. Department of Agriculture to keep it that way. ... leading a group of researchers to study the wheat blast ... Brazil. "We don,t know if our varieties in Kansas ...
... In the rogues, gallery of microscopic infectious agents, the prion ... both DNA and RNA, prions are believed to cause such ... and moose, mad cow disease in cattle, scrapie in sheep ... the weirdest infectious agent know to science, the prion is ...
... repair patterns may increase risk of pancreatic cancer by as ... 77 percent, depending on the genes involved, according to a ... Clinical Cancer Research , a journal of the American Association ... in late stages, and thus is resistant to most available ...
Cached Biology News:Researchers to use K-State's BSL-3 Lab for $1 million study of fungus threatening wheat crops 2Researchers to use K-State's BSL-3 Lab for $1 million study of fungus threatening wheat crops 3Common soil mineral degrades the nearly indestructible prion 2
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Biology Products: